Related Experiment Videos
Does intraprostatic vasopressin prevent the transurethral resection syndrome?
1Prasad's Hospital, Georgetown, Guyana, South America. deensh@guyana.net.gy
BJU International
|August 10, 2000
Summary
Intraprostatic vasopressin (IPVP) injection before transurethral resection (TURP) helps prevent TUR syndrome by reducing bleeding and improving visibility. This technique minimizes irrigant absorption, enhancing patient safety during the procedure.
Area of Science:
- Urology
- Surgical Innovation
- Patient Safety
Background:
- Transurethral resection (TUR) syndrome is a potential complication of transurethral prostatectomy (TURP).
- Fluid absorption during TURP can lead to electrolyte imbalances and other adverse effects.
- Preventing TUR syndrome is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of intraprostatic vasopressin (IPVP) in preventing TUR syndrome during prostatectomy.
- To assess the impact of IPVP on irrigant absorption and patient hemodynamics.
Main Methods:
- 36 patients undergoing TURP received transrectal IPVP injection before the procedure.
- Serum sodium and free hemoglobin levels were monitored.
- Patient vital signs and sensorium were continuously assessed.
- Breath alcohol levels were measured in patients receiving alcohol-added irrigant.
Main Results:
- No significant changes in clinical variables were observed during TURP with IPVP.
- Serum sodium levels showed only insignificant decreases in most patients.
- Minimal irrigant absorption occurred, with one exception linked to capsular damage.
- IPVP improved visibility by decreasing bleeding.
Conclusions:
- IPVP appears to prevent TUR syndrome by minimizing irrigant absorption.
- Reduced bleeding with IPVP aids in early identification of capsular damage, a key risk factor for fluid entry.
- IPVP is a potentially valuable adjunct for improving safety during TURP.